Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

US President’s FY 2012 Budget would create new user fees, ban patent settlements, and reduce BPCIA reference product exclusivity (FDA Law Blog) (IP Watch)

Role of public-sector research in the discovery of drugs and vaccines (PatentlyBIOtech) (IP Watch)

Antwerp Court of Appeal stops infringement of Valsartan/HCTZ SPC based on patent claiming Valsartan alone: Novartis v Teva (The SPC Blog)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

General

Pharma backs calls for extension of TRIPS deadline for least-developed countries (IP Watch)

Medicines Patent Pool in talks with Big Pharma (Spicy IP)

Protect Pharma sells patent portfolio to Grunenthal GmbH (GenericsWeb)

Australia: Federal Court upholds TGA decision to refuse access to documents relating to applications to list generics on the ARTG (IP Whiteboard)

EU clarifies statement on ARVs (GenericsWeb)

Mexico: Pharma patents in Mexico: an assessment of the current position (IP tango)

US: FDA announces its innovation pathway program for breakthrough technologies (FDA Law Blog)

US: President’s FY 2012 Budget would create new user fees, ban patent settlements, and reduce BPCIA reference product exclusivity (FDA Law Blog) (IP Watch)

US: Role of public-sector research in the discovery of drugs and vaccines (PatentlyBIOtech) (IP Watch)

US: Stanford Daily opines on policy issues with stem cell patents (IPBiz)

US: Abbott fails to stay patent dispute with Wyeth over stents (Patent Docs)

US: Does disclosure of laundry list of protein variants provide adequate written description for later claim to specific protein?: Novozymes v Danisco (Holman’s Biotech IP Blog)

US: Preliminary injunction softened after claims are rejected in reexamination: Celsis In Vitor v CellzDirect (Reexamination Alert)

Products

Alpharen – EU: General Court: Boards of appeal are judges not doctors!: Ineos Healthcare v OHMI – Teva (Class 46)

Androderm (Testosterone) – US: Watson settles with Promote Innovation in Androderm false marking suit (Patent Docs)

Asacol (Mesalamine) – US: Roxane sanctioned in Asacol patent dispute with Medeva (Patent Docs)

Detrol (Tolterodine) – US: Subsequent ANDA sponsor says Detrol LA patent has gotta go; But would a final court decision trigger 180-day exclusivity? (FDA Law Blog)

Diovan (Vasartan) – France: Novartis v Actavis – preliminary injunction for Valsartan confirmed (The SPC Blog)

Diovan HTC (Valsartan) – Belgium: Antwerp Court of Appeal stops infringement of Valsartan/HCTZ SPC based on patent claiming Valsartan alone: Novartis v Teva (The SPC Blog)

Lescol (Fluvastatin) – US: Novartis files patent infringement complaint against Mylan following Para IV challenge (Patent Docs) (GenericsWeb)

Mucinex (Guaifenesin) – US: Watson announces favorable District Court ruling in generic Mucinex patent suit (SmartBrief)

Nexium (Esomeprazole) – US: Astrazeneca files patent infringement complaint against Hanmi following Para IV certification filing (Patent Docs)

Reminyl (Galantamine) – EU: ECJ to hear Case C-427/09 Generics (UK) Ltd v Synaptech Inc 17 Feb (The SPC Blog)

Rogaine (Minoxidil) – US: Perrigo to settle Rogaine foam patent litigation with Stiefel Research Australia (GenericsWeb)

Tamiflu (Oseltamivir) – US: Natco Pharma challenges Gilead patent on Tamiflu (IPBiz) (GenericsWeb)

Viread (Tenofovir) – Brazil to produce generic version of medication for AIDS and hepatitis (GenericsWeb)

Xyrem (Oxybate) – US: Jazz Pharmaceuticals files patent infringement complaint against Roxane Para IV certification filing (Patent Docs)